TY - JOUR T1 - Reopening California : Seeking Robust, Non-Dominated COVID-19 Exit Strategies JF - medRxiv DO - 10.1101/2021.04.26.21256105 SP - 2021.04.26.21256105 AU - Pedro Nascimento de Lima AU - Robert Lempert AU - Raffaele Vardavas AU - Lawrence Baker AU - Jeanne Ringel AU - Carolyn M. Rutter AU - Jonathan Ozik AU - Nicholson Collier Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/28/2021.04.26.21256105.abstract N2 - Amid global scarcity of COVID-19 vaccines and the threat of new variant strains, California and other jurisdictions face the question of when and how to implement and relax COVID-19 Nonpharmaceutical Interventions (NPIs). While policymakers have attempted to balance the health and economic impacts of the pandemic, decentralized decision-making, deep uncertainty, and the lack of widespread use of comprehensive decision support methods can lead to the choice of fragile or inefficient strategies. This paper uses simulation models and the Robust Decision Making (RDM) approach to stress-test California’s reopening strategy and other alternatives over a wide range of futures. We find that plans which respond aggressively to initial outbreaks are required to robustly control the pandemic. Further, the best plans adapt to changing circumstances, lowering their stringent requirements to reopen over time or as more constituents are vaccinated. While we use California as an example, our results are particularly relevant for jurisdictions where vaccination roll-out has been slower.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe thank all our sponsors for their support. This research was funded by Mala Gaonkar and Surgo Foundation UK Limited, a separate legal entity to Surgo Ventures and the Anne and James Rothenberg Dissertation Award. The funding for the prior project to develop the epidemiological model was provided by gifts from RAND supporters and income from operations. We also thank the National Institute of Allergies and Infectious Diseases (R01AI118705) for providing support in projects that led to preliminary work and ideas that motivated this project. High-Performance Computing resources were provided by Laboratory Computing Resource Center at Argonne National Laboratory (Bebop cluster). Computing and labor resources provided by Argonne were funded by the U.S. Department of Energy, Office of Science, under contract number DE-AC02-06CH11357.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In this modeling study we only used secondary de-identified data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe code and data used in our analysis are available under a GPL-2.0 license. https://github.com/RANDCorporation/covid-19-reopening-california ER -